Display options
Cite
Shimamoto Y, Suga K, Shimojo M, et al. Comparison of CHOP versus VEPA Therapy in Patients with Lymphoma Type of Adult T-cell Leukemia. Leuk Lymphoma. 1990;2(5):335-40doi: 10.3109/10428199009106469.
Shimamoto, Y., Suga, K., Shimojo, M., Nishimura, J., Nawata, H., & Yamagughi, M. (1990). Comparison of CHOP versus VEPA Therapy in Patients with Lymphoma Type of Adult T-cell Leukemia. Leukemia & lymphoma, 2(5), 335-40. https://doi.org/10.3109/10428199009106469
Shimamoto, Y, et al. "Comparison of CHOP versus VEPA Therapy in Patients with Lymphoma Type of Adult T-cell Leukemia." Leukemia & lymphoma vol. 2,5 (1990): 335-40. doi: https://doi.org/10.3109/10428199009106469
Shimamoto Y, Suga K, Shimojo M, Nishimura J, Nawata H, Yamagughi M. Comparison of CHOP versus VEPA Therapy in Patients with Lymphoma Type of Adult T-cell Leukemia. Leuk Lymphoma. 1990;2(5):335-40. doi: 10.3109/10428199009106469. PMID: 27456924.
Copy Download .nbib Format: NLM
Share it on

Leuk Lymphoma. 1990;2(5):335-40. doi: 10.3109/10428199009106469.

Comparison of CHOP versus VEPA Therapy in Patients with Lymphoma Type of Adult T-cell Leukemia.

Leukemia & lymphoma

Y Shimamoto, K Suga, M Shimojo, J Nishimura, H Nawata, M Yamagughi

Affiliations

  1. a Division of Hematology, Department of Internal Medicine, School Medical School, Saga.
  2. b Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

PMID: 27456924 DOI: 10.3109/10428199009106469

Abstract

Forty-six Japanese patients with lymphoma type of adult T-cell leukemia (ATL) were treated with one of the 4-drug combinations, CHOP or VEPA regimen. Fourteen patients were treated with CHOP, while 32 were treated with VEPA. The complete response i(CR) rate and the 5-year survival rate of patients treated with CHOP were 35.7% and 7.1%, respectively, while for those treated with VEPA the rates were 43.8% and 18.7%, respectively. Only two patients treated with CHOP survived for more than 1 year, while the others died within 1 year. On the other hand, 13 patients treated with VEPA survived for more than 1 year. The 32 VEF'A-treated patients were divided into two groups according to the duration of survival: (A) 13 surviving for more than 1 year, and (B) 19 surviving for less than 1 year. They were compared for pretreatment characteristics. The differences between the two groups related to hepatomegaly, the presence of B symptoms, lactic dehydrogenase (LDH) and calcium levels. The results indicate that these factors are important in predicting the response and survival of patients with lymphoma type of ATL.

Keywords: Adult T-cell leukemia (ATL); combination chemotherapy; human T-cell leukemia virus type I (HTLV-I); non-Hodgkin's lymphoma (NHL)

Publication Types